Olufunmilayo Olopade to Combined Modality Therapy
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Combined Modality Therapy.
Connection Strength
0.155
-
Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast J. 2010 Jan-Feb; 16(1):110-2.
Score: 0.068
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
Score: 0.045
-
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43.
Score: 0.018
-
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol. 2008 Sep; 3(9):1003-11.
Score: 0.016
-
Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apher. 1999; 14(4):171-6.
Score: 0.008